Rapid AI-powered fungal pathogen identification. Better health outcomes through rapid AI-powered identification of fungal pathogens.
BioSciAI develops AI-powered technology to identify fungal pathogens directly from patient samples. At the bedside, in under an hour.
The next pandemic won’t wait. Neither should your diagnosis.
- Peer-reviewed × 3 3 peer-reviewed publications
- AICE-funded Alberta Innovates AICE grantee
- U of A startup University of Alberta startup
The silent pandemic hospitals can no longer ignore.
Fungal infections, especially invasive candidiasis, are surging. Multidrug-resistant Candidozyma auris (previously known as Candida auris) has spread across the globe.
Traditional diagnostics take days, delaying life-saving therapy, prolonging hospital stays, increasing morbidity and mortality, and driving healthcare costs skyward.
Under one hour. 100% confidence. BioSciAI aims to deliver.
BioSciAI's diagnostic platform aims to deliver accurate fungal pathogen identification, with greater than 90% overall accuracy, directly at the bedside in any healthcare setting.
- Rapid.
- Results in minutes, instead of days.
- Accurate.
- >90% accuracy across life-threatening fungal pathogens.
- Accessible.
- No specialized laboratory, equipment, or advanced training required.
- Affordable.
- Dramatically lower cost per patient compared to conventional diagnostic methods.
Sample in. Species out.
A diagnostic workflow engineered to fit inside a point-of-care testing device, from clinical sample to species-level identification.
We're building the frontline defense against the next pandemic, which experts warn could be fungal.
Contact us for partnership or collaboration. And if you're an investor, contact us for more details on how to fund us.